2. Academic Validation
  3. In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria

In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria

  • Clin Exp Pharmacol Physiol. 2023 Apr 22. doi: 10.1111/1440-1681.13777.
Anqi Li 1 2,  Zhili Tan 1 2,  Siyuan He 1 2,  Haiqing Chu 1 2 3
Affiliations

Affiliations

  • 1 Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
  • 2 School of Medicine, Tongji University, Shanghai, China.
  • 3 Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
PMID: 37086075 DOI: 10.1111/1440-1681.13777
Abstract

Non-tuberculous mycobacterial infections are gradually increasing worldwide, with slow-growing mycobacteria such as Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium kansasii accounting for the majority of cases. The use of tetracyclines has received renewed attention in recent years, and this study was designed to investigate the Antibacterial activity of omadacycline, eravacycline, tigecycline, sarecycline, minocycline and doxycycline against M. avium, M. intracellulare and M. kansasii. Susceptibility testing of six tetracyclines was conducted against M. avium, M. intracellulare and M. kansasii isolates, and all the clinical isolates were collected from January 2012 to December 2018. All six agents exhibited poor Antibacterial activity against slowly growing mycobacteria (SGM) isolates of three subspecies with MIC50 and MIC90 ≥8 μg/mL. M. intracellulare and M. kansasii had lower resistance rates to omadacycline than the other five drugs. The severe resistance of SGM to Tetracycline suggests that developing tetracycline-class Antibiotics needs to overcome existing resistance mechanisms.

Keywords

Mycobacterium avium; Mycobacterium intracellulare; Mycobacterium kansasii; doxycycline; eravacycline; minocycline; omadacycline; sarecycline; tigecycline.

Figures
Products